By Bryan Koenig ( October 11, 2018, 10:03 PM EDT) -- Federal Trade Commission staff attorneys urged the commission in oral arguments Thursday to revive a pay-for-delay case against Impax over the opioid pain medication Opana ER, arguing that brandmaker Endo Pharmaceuticals Inc.'s payment of more than $100 million to the generics company was meant to avoid competition....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.